Detail akcie Kiora Pharma Rg online

Business Summary: Kiora Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company, which is engaged in developing and commercializing therapies for the treatment of retinal diseases. The Company is engaged in developing KIO-301, a vision-restoring small molecule that acts as a photoswitch specifically created to restore vision in patients with inherited and age-related degenerative retinal diseases, including retinitis pigmentosa (RP). It is also developing KIO-104 for the treatment of retinal inflammatory diseases, including Diabetic Macular Edema (DME) and Posterior Non-Infectious Uveitis, a rare T cell-mediated, intraocular inflammatory disease. KIO-104 is a non-steroidal small-molecule inhibitor of dihydroorotate dehydrogenase (DHODH) formulated for intravitreal delivery and is ideally suited to suppressing overactive T-cell activity to treat the underlying inflammation. KIO-101 focuses on treating the ocular manifestation of patients with autoimmune diseases.
Financial Summary: BRIEF: For the six months ended 30 June 2025, Kiora Pharmaceuticals Inc revenues decreased from $16M to $0K. Net loss totaled $4.3M vs. income of $11.2M. Revenues reflect Grant Revenue decrease from $20K to $0K. Net loss reflects Research and Development Expense - Balan increase from $2.2M to $4.9M (expense), Change in Fair Value of Contingent Consi increase from $108K to $413K (expense).